GlassScriptPhysician profile
Michael Mgerian
NPI 1023674231
$5,014.47
in general payments reported to CMS, 2019-2025
35 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $360 · 2023: $1,423 · 2024: $1,644 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,654.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,081.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $621.80 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $511.71 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $425.98 | 2022-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.74 | 2022-2025 | Jardiance |
| Inspire Medical Systems, INC. | $193.29 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $183.16 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.01 | 2022-2025 | Xifaxan |
| Pfizer INC. | $169.72 | 2023-2025 | |
| Exact Sciences Corporation | $159.41 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $137.12 | 2025 | Voquezna |
| Inari Medical, INC. | $135.83 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Supernus Pharmaceuticals, INC. | $133.16 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $127.95 | 2022-2024 | Quviviq |
| Abiomed | $109.18 | 2024-2025 | Impella |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $99.39 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $58.04 | 2022-2025 | |
| Corium, LLC | $50.66 | 2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $49.81 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $49.19 | 2022-2023 | Belsomra, Steglatro, Steglujan |
| Astellas Pharma US INC | $42.74 | 2023-2024 | Veozah, Myrbetriq |
| Gilead Sciences, INC. | $33.64 | 2023-2024 | |
| Abbott Laboratories | $23.12 | 2023 | Proclaim |
| Edwards Lifesciences Corporation | $22.03 | 2025 | Sapien 3 Ultra Resilia |
| Axonics, INC. | $21.25 | 2024 | Axonics |
| Azurity Pharmaceuticals, INC. | $19.85 | 2025 | Edarbi |
| Procept Biorobotics Corporation | $19.18 | 2024 | Aquabeam System |
| Takeda Pharmaceuticals U.S.A., INC. | $18.57 | 2022 | |
| Abbvie INC. | $17.66 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $15.96 | 2025 | Lumryz |
| Bausch Health US, LLC | $15.52 | 2025 | Aplenzin |
| Hikma Pharmaceuticals USA | $14.43 | 2024 | Ryaltris |
| Neos Therapeutics, LP | $13.79 | 2024 | Adzenys Xr-Odt |
| Amarin Pharma, INC. | $12.94 | 2023 | |
| Radius Health, INC. | $12.93 | 2023 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mgerian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.